+ Follow
Source: Radwan Menzer on pexels.com

Most people have never heard of the Nipah virus. It does not trend the way influenza does, and it has never triggered the kind of global panic that COVID-19 did. Yet among infectious disease specialists, it occupies a very specific kind of dread — the category of pathogens that are rare enough to be unfamiliar but lethal enough to be catastrophic. Since its first confirmed appearance in 1998, Nipah has killed more than 415 of the approximately 750 people it has infected worldwide. That is not a rounding error. That is a case fatality rate sitting between 40 and 75 percent, depending on where the outbreak occurs and how quickly it is caught. There is no approved cure. There is no licensed vaccine. And as of early 2026, it is still circulating.

What makes Nipah particularly difficult to ignore is not just its lethality but its pattern of behaviour. It keeps coming back. Kerala, India, has experienced nine separate Nipah outbreaks since 2018. Bangladesh has seen infections in nearly every year since 2001. And in January 2026, two healthcare workers in West Bengal, India, both between 20 and 30 years old, tested positive via RT-PCR and ELISA testing at the National Institute of Virology in Pune, confirming the third Nipah outbreak ever recorded in that state. They had developed symptoms consistent with severe Nipah infection in late December 2025. The response was immediate: airports across Thailand, Malaysia, Indonesia, and Hong Kong ramped up screening for travelers from the affected region. None of that response was an overreaction. Every Nipah case is taken seriously because the virus has earned that seriousness the hard way.

Where It Came From and Why It Keeps Finding Us

Nipah virus takes its name from Sungai Nipah, a village in the Malaysian state of Negeri Sembilan. In 1998 and 1999, pig farmers in that area began dying from an unexplained encephalitis, a brain inflammation, that baffled clinicians. By the time the outbreak was identified and controlled, more than 100 people had died in Malaysia and Singapore, and over one million pigs had been culled in an attempt to stop transmission. Scientists eventually traced the original source to Pteropus fruit bats, large flying foxes whose geographic range stretches from South Asia across Southeast Asia and into Australia. The bats carry the virus without any visible illness. Their immune systems tolerate it. Human immune systems do not.

The path from bat to human most commonly runs through two routes. In Malaysia and the Philippines, pigs served as the amplifying intermediate host, eating fruit contaminated with bat droppings and then spreading the virus to farmers and slaughterhouse workers. In Bangladesh and India, the route is more direct. Raw date palm sap, a traditional drink harvested during the winter months, is collected by placing open clay pots at the base of palm trees. Fruit bats visit those trees at night, contaminating the sap with their saliva and urine. The WHO and Bangladesh's Institute of Epidemiology, Disease Control and Research have documented that nearly half of all primary Nipah cases in Bangladesh, 162 of the 347 total cases recorded through September 2025, were directly linked to consuming raw date palm sap or its fermented version, tari. Another 29 per cent of cases resulted from direct human-to-human transmission.

The seasonal pattern matters. In Bangladesh, the harvesting of date palm sap runs roughly from November to March, and that window reliably corresponds with the peak period for Nipah spillover events. Outside that window, transmission becomes less common, though not impossible. In 2025, Bangladesh reported one fatal case in a child from Naogaon district with no history of date palm sap consumption and no clear source of infection, occurring outside the usual season. That case remains under investigation, and it underscores how much remains unknown about the virus's full range of transmission possibilities.

What the Virus Does Inside the Body

Nipah is classified as an enveloped, negative-sense, single-stranded RNA virus in the family Paramyxoviridae, the same broad viral family that includes measles. It belongs to the genus Henipavirus, meaning it shares structural characteristics with Hendra virus, another bat-borne pathogen. The virus enters the body through mucous membranes in the nose, mouth, or eyes. Once inside, it attaches to a protein called ephrin-B2, which is found in abundance in the central nervous system and in blood vessel walls throughout the body. This explains with precision why Nipah causes such severe brain and vascular damage. The virus is essentially using the nervous system's own structural protein as a doorway.

Inside infected cells, Nipah forces neighbouring cells to fuse into large, multinucleated masses called syncytia. This mechanism allows the virus to spread between cells while partially evading the immune system's defences. It simultaneously uses those hijacked cells to manufacture thousands of new viral copies before the cells die. The resulting immune response triggers severe inflammation. In the brain, this produces encephalitis: swelling, disorientation, seizures, personality changes, and in many cases, coma. In the lungs, the virus can cause a condition similar to acute respiratory distress syndrome, where fluid accumulates in the air sacs and oxygenation becomes critically impaired.

The incubation period, the gap between exposure and the onset of symptoms, typically runs between 3 and 14 days, though rare cases have shown incubation periods of up to 45 days. Early symptoms are almost indistinguishable from dozens of less serious infections: fever, headache, muscle pain, sore throat, and vomiting. It is only as the disease progresses into its neurological and respiratory phases that the picture becomes definitively and devastatingly Nipah. By the time a patient is seizing, losing consciousness, or struggling to breathe, the virus has already done substantial damage, and medicine currently has nothing specific to offer beyond keeping the body functioning while it fights.

The 2018 Kerala Outbreak: A Case Study in Both Loss and Response

Of all the outbreaks that Kerala has experienced since Nipah first arrived there in 2018, the original episode remains the most instructive, both for its devastation and for how health systems can respond when a completely unknown killer appears. The index patient, a man from Kozhikode district, fell ill in early May 2018 and died before a diagnosis was confirmed. By then, he had already infected 16 people at the Medical College Hospital in Kozhikode. Among the victims was Lini Puthussery, a nurse who had cared for him without knowing what she was dealing with. She died before Nipah was identified. In a letter she wrote to her husband in her final days, she asked him to take care of their children and told him not to feel bad. She said she had done her duty. The letter was shared widely across India and became a quiet emblem of the human cost borne by healthcare workers confronting unknown outbreaks.

The 2018 Kerala outbreak ultimately produced 23 confirmed and probable cases and a case fatality rate of 91 percent. The state government quarantined more than 2,000 contacts across Kozhikode and Malappuram districts. An experimental monoclonal antibody called m102.4 was imported from Australia. It had shown promise in animal studies but had never been used widely in humans. The outbreak was declared over on June 10, 2018, approximately five weeks after it began. Kerala's response, including rapid contact tracing, early lab confirmation in partnership with the National Institute of Virology in Pune, transparent public communication, and swift mobilization of central and state health authorities, became a reference point for how to manage an emerging Nipah event. Subsequent outbreaks in 2021, 2023, 2024, and 2025 each demonstrated both how much the system had learned and how persistently the virus returned.

The 2025 outbreak, which spread across Palakkad and Malappuram districts, produced four confirmed cases and two deaths. Contact tracing identified 723 individuals across five districts, Palakkad, Malappuram, Kozhikode, Ernakulam, and Thrissur, who had come into contact with confirmed cases. It was the ninth time Kerala had been through this in seven years. That number tells its own story about the relentless pressure Nipah continues to exert on one of the world's most at-risk regions.

Survivors and the Long Aftermath

The death toll is the number most commonly cited when discussing Nipah. But it does not capture the full picture of what the virus does to people. Survivors often find that recovery from the acute illness is only the beginning of a longer and more complicated journey. Because Nipah inflicts significant damage on the central nervous system, researchers have documented a range of lasting neurological effects in people who survive the initial infection. These include memory impairment, difficulty concentrating, personality changes, seizures, movement disorders, speech difficulties, and chronic fatigue. Mental health consequences, depression and anxiety among them, are also commonly reported in survivor cohorts.

Perhaps the most striking aspect of Nipah survivorship is a phenomenon known as late-onset or relapsing encephalitis. In a small but documented proportion of cases, individuals who appeared to have fully recovered from Nipah later develop renewed neurological symptoms, sometimes weeks, sometimes months, and in documented cases as long as eleven years after the original infection. Research published in peer-reviewed literature has identified more than 20 cases of relapsing Nipah encephalitis, including at least one instance in which the relapse followed an entirely asymptomatic original infection, meaning the person had no idea they had ever carried the virus. The icddr,b in Bangladesh has operated the world's longest-running Nipah surveillance system and follows the world's largest cohort of Nipah survivors. Their ongoing work has also reported evidence of long-term immune durability in survivors that could eventually inform vaccine design.

These long-term complications receive minimal attention in global health discussions, which tend to focus on outbreak containment and case fatality numbers. For survivors managing persistent neurological deficits with little to no specialist support, particularly in rural Bangladesh or Kerala, the story does not end at discharge.

No Cure, No Vaccine and Why That Has Taken So Long

Nipah virus has been known to infect humans since 1998. Twenty-seven years later, there remains no licensed drug that targets it and no approved vaccine to prevent it. That gap is not an accident. It reflects structural realities in how global health priorities have historically been set. Nipah outbreaks are small, geographically concentrated, and overwhelmingly affect low-income communities in South Asia. They do not generate the commercial demand that drives pharmaceutical investment. The incentive structure that produces treatments for high-prevalence chronic conditions in wealthy countries has never applied to a virus that kills dozens of people per year in Bangladesh and Kerala.

Treatment today is entirely supportive. Clinicians keep patients oxygenated, manage fluid balance, treat seizures, and attempt to limit secondary complications through intensive care. There is no antiviral drug with proven efficacy. Ribavirin was used during the original Malaysian outbreak, but its impact on outcomes has never been conclusively established in controlled trials. The monoclonal antibody m102.4, used experimentally in Kerala in 2018 and imported from Australia, completed Phase I safety trials but has not progressed to widespread availability. In 2023, Remdesivir was administered to patients during a Kerala outbreak, with some physicians citing improved outcomes, though this remains anecdotal in the absence of randomized trial data.

The WHO has listed Nipah as a priority pathogen on its Research and Development Blueprint for Epidemics, a designation intended to attract investment toward diseases with pandemic potential. CEPI, the Coalition for Epidemic Preparedness Innovations, has committed approximately $150 million to its Nipah research and development portfolio. That investment is real, and its effects are beginning to show. But the fundamental structural problem remains: efficacy trials are almost impossible to run when outbreaks are small and unpredictable, and no trial can enroll thousands of participants in a disease that rarely infects more than a handful of people at once.

The Race for a Vaccine and What Is Actually Happening Right Now

The most concrete progress on a Nipah vaccine belongs to the University of Oxford's Pandemic Sciences Institute. Their candidate, ChAdOx1 NipahB, uses a chimpanzee adenoviral vector to deliver a Nipah surface protein that primes the immune system to recognize and fight the virus. Phase I trials enrolling 51 healthy adults between 18 and 55 began in Oxford in January 2024, and all participants safely completed one year of follow-up with results expected in 2026.

In December 2025, Oxford launched the world's first Phase II clinical trial of a Nipah vaccine candidate. The trial is taking place in Bangladesh, the country with the longest documented history of annual Nipah outbreaks, in partnership with icddr,b and funded by CEPI. It will enroll 306 healthy participants aged 18 to 55 and assess both the safety and the immune response generated by ChAdOx1 NipahB in a population that actually faces ongoing exposure to the virus. In June 2025, the European Medicines Agency granted ChAdOx1 NipahB its PRIME designation, a status given to medicines addressing serious unmet medical needs that allows for accelerated regulatory review. In October 2025, CEPI committed up to $7.3 million to enable the Serum Institute of India to produce Phase II trial material and create an investigational reserve of up to 100,000 doses that could be deployed under a research protocol during a future outbreak.

Other candidates are also advancing. Gennova Biopharmaceuticals, in partnership with Houston Methodist Research Institute, announced a self-amplifying mRNA Nipah vaccine candidate in March 2025, backed by up to $13.38 million in CEPI funding. A Nipah monoclonal antibody called MBP1F5 is expected to enter early-to-mid-stage clinical trials in a Nipah-affected country in 2026. CEPI's programme lead Rick Jarman has estimated that a Nipah vaccine could reach licensure within five years, contingent on Phase II data and regulatory collaboration. That estimate is cautiously optimistic, but it represents more forward movement on Nipah than has existed at any previous point in the 27-year history of the disease.

Why the Rest of the World Should Be Paying Attention

It is reasonable to ask why Nipah, a disease that has infected roughly 750 people over 27 years, warrants global concern. The answer is not that Nipah is currently spreading widely. The WHO consistently assesses the international risk as low following each outbreak. The answer is what Nipah could become under different circumstances, and how close those circumstances could be.

Fruit bats in the Pteropus genus, the natural reservoir of Nipah virus, are distributed across a range that encompasses South Asia, Southeast Asia, and parts of Australia and the Pacific, covering regions home to more than two billion people. The virus already demonstrates efficient human-to-human transmission in healthcare settings and through close household contact. Approximately 20 percent of all Nipah cases in Kerala have involved nosocomial transmission, meaning spread within hospitals, before infection control measures were tightened. The virus is capable of causing fatal illness in healthcare workers who are unaware they are being exposed, as the 2026 West Bengal cases demonstrated.

Pandemic preparedness experts place Nipah near the top of priority pathogen lists not because of its current trajectory but because of its characteristics: high lethality, documented human-to-human spread, a large and geographically distributed animal reservoir, and zero approved countermeasures. COVID-19 demonstrated what a novel pathogen can do when those factors align with transmissibility at scale. Nipah does not yet have COVID-19's transmissibility. But it exists on a continuum, and changes in land use, agricultural practices, bat habitat loss, and human encroachment into previously undisturbed ecosystems could alter that equation. Deforestation pushing bat colonies into closer proximity with human settlements has been cited repeatedly in the scientific literature as a structural driver of spillover events.

What Can Actually Be Done Right Now

Because no vaccine or treatment is yet approved, prevention remains the only tool available to communities in high-risk areas. Covering date palm sap collection pots with bamboo skirts or physical barriers at night to exclude bats reduces contamination. Boiling raw sap before consuming it eliminates the virus. Avoiding fruits that show signs of bat contact reduces exposure risk. Thorough handwashing after handling animals or caring for sick individuals matters. During confirmed outbreak periods, healthcare workers must use full personal protective equipment, and hospitals need to implement strict infection prevention protocols including isolating suspected cases before confirmation.

At the system level, states and countries in the Nipah belt cannot afford to build response capacity only when an outbreak is already happening. Kerala's experience since 2018 has produced institutional knowledge, laboratory infrastructure through partnerships with NIV Pune, mobile lab units deployable to affected districts, and trained rapid response teams. Each new district that encounters Nipah for the first time, as Palakkad did in 2025, is starting from scratch at the local level regardless of how much the state system has learned. Sustained investment in disease surveillance, healthcare worker training, diagnostic networks, and risk communication needs to be an ongoing baseline, not an emergency measure triggered after cases appear.

A Virus that has Waited Long Enough for an Answer

Nipah virus has been killing people since 1998. It has claimed more than 415 lives from approximately 750 documented infections. It has left survivors with lasting neurological damage, relapsing encephalitis years after apparent recovery, and limited access to the kind of specialist care those conditions require. It has sent healthcare workers to their deaths while they performed the ordinary duties of their jobs. And for 27 years, it has done all of this without prompting the development of a single licensed treatment or vaccine.

That is changing, slowly, imperfectly, but in ways that are now measurable. The Oxford ChAdOx1 NipahB vaccine is in Phase II trials in Bangladesh. CEPI has built a $150 million research and development portfolio around the virus. The Serum Institute of India is manufacturing an investigational reserve of 100,000 doses. Monoclonal antibodies are entering clinical trials. The European Medicines Agency has granted accelerated regulatory status to the most advanced candidate. These are not abstractions. They are specific, funded, running programs.

But science moves on its own timeline, and 2026 has already produced new Nipah cases in West Bengal and continued spillover events in Kerala. The virus is not waiting for clinical trials to finish. The most immediate defenses available remain what they have always been: early detection, rigorous contact tracing, honest public communication, and the willingness of healthcare workers and public health systems to treat every suspected case as a potential outbreak in its earliest hour. The virus has no cure yet. The response still does.

References

.     .    .

Discus